Novel drugs are dynamically changing current treatment regimens for multiple myeloma (MM). Novel drugs have improved prognosis of MM patients in clinical studies but are expensive. Little is known about up-to-date real-world application and costs.
Background
Multiple myeloma (MM) is the second most frequent hematologic malignancy in Switzerland. Incidence of MM is increasing since 1990 world-wide [1] and it presents a considerable burden to patients and the health care system. [2] Novel drugs (e.g. bortezomib, lenalidomide, carfilzomib) have considerably changed current treatment regimens for MM. Novel approaches have also improved prognosis of MM patients but are expensive. [2] [3] [4] Updated guidelines for Switzerland [2] and for Europe [3] advise clinicians regarding the translation of current evidence derived from clinical studies into treatment strategies in clinical practice to secure patient benefit.
Little is known, however, regarding the use of current MM treatment regimens in routine clinical practice, associated costs and mortality in the real-world setting. [5, 6] For Switzerland, data exist only from a pan-European study with very few Swiss patients included. [7, 8] Health care claims data cover a large population and are increasingly used in health services research. They are usually reliable as they underly multiple check procedures and represent a well-established approach to collect and analyse realworld treatment data and costs. Such data allow quantifying the medical and economic burden of a disease to better understand current public health challenges and to optimise resource allocation. We therefore used health care claim-based data to describe the current real-world patterns and associated costs of MM treatment in Switzerland.
Methods

Study design
We performed a retrospective, observational study (cost-outcome description [9] ).
We used the claims database of consecutive cases of a major national Swiss health insurance company, which covers about 14% of the Swiss population (Helsana Versicherungen AG).
According to the Human Research Act in Switzerland, approval from a local Ethics committee was not required for studies using an anonymised database. The study was partly funded by Amgen Switzerland. The funding party had no influence on the concept of the study, data collection, analysis or interpretation of results.
Study period and patients
Data were collected from the complete calendar years 2012 to 2017. To be included, cases had to be insured with Helsana health insurance for the complete calendar year (prevalence view). In addition, complete three preceding years without identification of MM were required to allow the inclusion as incident cases (incidence view). In case of death, cases were included even if their Helsana health insurance coverage was less than 12 months in that year.Thus, prevalent cases relate to the years 2012 to 2017 , incident cases to the years 2015 to 2017 (Supplement: Figure   S1 ). For analyses of treatment lines and costs, we relied on the incident population, because in this population we could unequivocally identify the first and subsequent treatment lines of each given case.
Inclusion criteria
The used health insurance database holds no direct information concerning the diagnosis of their patients treated in the outpatient sector. Thus, we had to rely on an algorithm using primary and secondary inclusion criteria for MM. For patients with inhospital treatment we used ICD10 diagnosis codes as primary identification (C90.0
Multiple myeloma).
For patients without hospitalisation and without the respective ICD code hospital discharge codes for identification of MM, we applied a filter algorithm for specific drugs to select patients suffering from MM with a very high probability (secondary inclusion criteria). Approved and reimbursed MM drugs in Switzerland (bortezomib, carfilzomib, ixazomib, lenaladomide, pomalidomide, elotuzumab, daratumumab)
were identified via ATC-codes, as well as other drugs mostly used in the context of MM treatment (e.g. Bendamustin; Melphalan; Dexamathasone; Zoledronate). Of these identified cases, we excluded those with additional use of Rituximab (as an indicator for non-Hodgkin lymphoma), and with the use of iron chelators (e.g. desferoxamine, as an indicator for Myelodysplastic Syndrome).
Information from claims database
Data were collected for the study population (per person per year) for demographic attributes (e.g. age, gender, death [yes/no]), health insurance attributes (e.g. managed care coverage [yes/no]), sequence of MM medications to identify treatment regimens, hematopoietic stem cell transplantation (HSCT: Swiss-DRG codes: A15C autologous; A04C allogeneic) and in-hospital stay due to MM.
Validated death data of the years 2012 and 2013 were taken from an earlier pilot study. This was necessary as a recoding for some variables in the insurance database took place during the observation period. Thus, prevalence figures used as denominators for calculation of death rates in 2012 and 2013 are not identical with prevalence figures reported in our study for other outcomes than death.
Treatment patterns
We grouped MM treatments according to the major drug backbone into drug regimens (Table S1 ): The PI-based regimen for the proteasome inhibitor concept (e.g. bortezomib), the immunomodulatory (IMID)-based regimen (e.g. lenalidomide), the CHEMO-(chemo therapy-) based regimen (e.g. bendamustin) and the MAB-(monoclonal antibody)-based regimen (e.g. Elotuzumab) [10] [11] [12] . In addition, a hierarchy of regimens was defined (PI > IMID > CHEMO > MAB) to meaningfully group simultaneously prescribed MM drugs to MM regimens. For example, if bortezomib and lenalidomide were applied within one drug regimen, the regimen was defined as PI-based regimen; if lenalidomide and bendamustin were applied within one drug regimen, the regimen was defined as IMID-based regimen.
As a pragmatic compromise, we defined a new treatment line as a MM treatment regimen after a "watch and wait phase" of at least 180 days without prescription of a MM specific drug (i.e. PI-; IMID-; CHEMO-; MAB-drug). As no information was available in the claims database about the reasons for change of treatment (e.g. due to relapse or side effects) or treatment breaks (e.g. due to remission), we performed a validation study to better understand prescription patterns of MM drugs in our claims database. A visual inspection of diverse MM drug patterns of 16 example patients showed that a shorter period than 180 days (for example, 60 days) would erroneously detect a "new line" also in cases where clearly no new line was visible in the validation patterns. Current Swiss guidelines recommend repetition of drug regimens after 21 days to 6 weeks within a treatment line [2] and prescription can be given (and, thus, claims can exist) for several cycles together. For example, one prescription of 5 drug packages at a time of the same MM drug may hold for 5 therapy cycles within the same treatment line (5 x 28 days = 140 days).
Consequently, the next prescription of the same drug within the same treatment line after 140 days would mimic a new line, if the limit would be set at, for example, 60 days and not at 180 days.
Health economic analysis
Analysis was done from the perspective of a third party payer (Helsana Insurance AG). In Switzerland, in-hospital drug costs are in general included in the Swiss-DRG tariffs and not separately reimbursed by health insurers. In the outpatient sector, health insurers pay each drug prescription on a fee-for-service base.
Direct medical costs (e.g. total medication cost of MM medications listed in inclusion criteria) were defined from the database via number of reimbursed units (e.g. prescribed medication package) multiplied with current Swiss basic health insurance tariffs (OKP) per unit. Costs for in-hospital treatment in Switzerland are based on Swiss-DRG cost weights multiplied with a base rate (45% of in-hospital treatment are paid by the patients' mandatory health insurance and included in our study; 55% by public authorities [cantons] and not included in our study). Costs are presented as 2017 Swiss Francs (CHF; official 2017 conversion rate to Euros: 0.85). [13] Out-ofpocket payments and deductibles of the patients were not accounted for. In addition, we did not apply a discount rate for costs due to the short observation period.
The extrapolation of costs to the Swiss population was performed with Helsana market shares per stratum as defined in the Swiss risk compensation scheme to adjust for differences across demographics between the Helsana population and the general Swiss population.
[14] The applied attributes for defining the strata were age group, canton of residence and gender which result in 32 groups per canton of residence.
Statistical analysis
For our descriptive analysis, we used means (standard deviation) or medians (interquartile range [IQR]) for continuous variables and proportions for categorical data. For inferential analysis, we applied parametric and non-parametric tests and pvalues <0.05 were considered significant. R was used for data analysis: R version 
Results
Patient population
We 
Drug treatment patterns
Of 378 incident patients, 292 (77.2) provided outpatient drug data with a mean followup of 2.1 years between 2015 and 2017 to assess drug treatment in further detail.
For 1 st -line therapy, PI-based regimens were the most frequent approach (76.0%), followed by IMID-based (21.9%) and CHEMO-based regimens (2.1%; Figure 2 ). Only four patients were treated with MAB-drugs, three times as part of PI-based regimens and once as part of an IMID-based regimen.
Age distribution across 1 st -line therapies showed a decrease of the younger age population from PI-based (age group <=75 years: 59%), over IMID-based (48%) to CHEMO-based (17%) regimens ( Table 2) .
Mean duration of 1 st -line treatment in 2015 and 2016 was between 210 and 298 days
for PI-based regimens, between 197 and 327 days for IMID-based regimens and between 30 and 61 days for CHEMO-based regimens (Table S2) 
Hematopoietic stem cell transplantation
From 2012 to 2015, 161 of 1054 MM patients (15.3%) were treated with autologous HSCT, four patients were treated with allogeneic HSCT (Table S3 ). All patients with HSCT were younger than 75 years with a balanced gender distribution as in the total prevalence population of 1054 MM patients.
Deceased MM patients
The proportion of deceased patients per year showed a systematically decreasing trend (p for trend: 0.03) during the observation time from 2012 to 2017 ( Figure 3 ).
Treatment costs for MM
Direct medical costs for MM specific drugs per patient per treatment regimen varied considerably between regimens, as well as between years (Table 3) Table S3 ).
We extrapolated annual outpatient MM drug costs to the general population of Switzerland ( 
Discussion
In our observational study of a claims database we analysed real-world treatment data of unselected MM patients in Switzerland in the era of novel MM drugs. PIbased regimens were the by far most frequent 1 st -line therapy, followed by IMID- 
Strengths and limitations
We applied real-world data of a major Swiss health insurance that provided treatment information about unselected MM patients from all parts of the country. The database has been used in several health services research studies in different clinical domains. [15] [16] [17] Our study has, however, several limitations. First, we were not able to use clinical charts of single patients to verify diagnosis, provide information about staging or analyse MM drug treatment and new treatment lines directly from chart reviews in detail (e.g. to study separation of induction and maintenance therapy or reasons for ending treatment). Thus, we were only able to include MM patients who had ever received MM drug treatment or have been treated for MM in a hospital. However, our filter criteria were developed in cooperation with clinical experts and the chosen filter variables also used ICD-coded diagnoses of inpatient treatments. For definition of a new treatment line we used a pause of drug prescription of 180 days as a pragmatic approach in the light of Swiss guidance for MM treatment [2] and the reported realworld drug prescription modes by our clinical experts. Second, the chosen definition of three calendar years free of a MM drug prescription or an in-hospital stay without MM diagnosis for incident cases may still have been too short. Thus, we cannot exclude a misclassification of some prevalent cases as incident cases but this may be a rare event. Third, we do not recommend using the extrapolated MM prevalence and incidence figures for epidemiological questions. Our extrapolated estimates are likely to be too high as compared with published data that were properly adjusted for European standard populations. Fourth, we did not have direct information about comorbidities of patients. However, using the validated ATC-codes for medically treated co-morbidities, [15] we have evidence, that the co-morbidity profile of outpatients remained basically similar over the observation period. Fifth, some results may not be reliable due to a short observation time window for patients who entered the study late. For example, for the analysis of the sequence of treatment lines, study population with suitable data is decreasing rapidly from line to line. Furthermore, TTNT may be underestimated for patients who entered the sample in 2017 due to the relatively short time window until end of observation period. Finally, the Helsana population is somewhat older than the Swiss general population and not all parts of Switzerland were equally represented in our study. However, extrapolating the costs to the country level we accounted for age differences, canton of residence and gender.
Recent publications with real-world data of MM patients
We compared our findings with recently published real-world treatment data of MM patients. An observational study from 6 countries [7, 8] included also data from one Swiss hemato-oncological centre: These cross-country findings are, however, difficult to compare with our results, as the European authors performed chart reviews of patients seen during consultation and could, thus, provide detailed clinical information but no figures about mortality rates and costs.
In the multi-country study [7] , the rate of patients receiving a 2 nd -line (61%) and a 3 rdline therapy (38%) is higher compared with the findings in our incident population (2 nd -line: 19%; 3 rd -line therapy: 1%). This may be partly explained with the longer time since diagnosis (median: 33 months) in the multi-national sample. [7] In addition, stem cell transplantation is less frequent in our sample (15% vs. 31%). Treatment patterns are similar with the most frequent 1 st -line drug bortezomib (EU: 48%; PIbased regimen in our analysis: 76%). Lenalidomid is the most frequent drug for 2 ndline (EU: 59%; IMID-based regimen in our analysis 56%) and 3 rd -line therapy (EU: 63%; our findings: 67%. [7] A real world study from the US with data from 2006 to 2014 found a similar pattern. [6] Treatment free intervals between lines (TTNT) in the EU study are between 10 months (median; after 1 st line) and 5 months (after 2 nd line). [8] We found a mean TTNT after 1 st -line between 7 and 13 months, for IMID-and PIbased regimens in 2015 and 2016).
A real-world study from the Netherlands assessed treatment costs in MM patients. [5] Even though this study assessed costs between 2001 and 2009, acquisition costs for novel MM agents accounted for about one third of total monthly inpatient and outpatient costs in the Netherlands at that time. We did not calculate total health care costs per patients of our sample, as we were mainly interested in diagnosis specific costs of MM treatment. However, it is likely that the increase in costs in our study for novel MM drugs in Switzerland from 2012 to 2017 accounts for more than one third of treatment costs in our MM patients.
HSCT was performed in 15.3% of prevalent patients in our study. This is a similar fraction as in other real-world populations from the US [6] (data from 2006 to 2014: 16.2%) or from the Netherlands [5] (data from 2001 to 2009: 20%). The European multi-country study [7] showed a higher fraction of HSCT (data from 2014: 31%), which may be due to an over-representation of patients from University oncology centers.
Implications for clinicians and public health decision makers
Our study provides evidence, that initial drug treatment regimens show little variability in accordance with current guidance. [2] However, variability of treatment patterns is increasing for 2 nd -and 3 rd -line therapy in our real-world data. Unexpected toxicities or patient preferences may contribute to such modifications.
Our study shows a significant increase in daily drug costs for MM patients over a six year period, on the patient level as well as on the Swiss country level. For example, the introduction of new agents, such as pomalidomide or monoclonal antibodies, was not associated with a decrease in costs for other myeloma drugs. The doubling of costs for novel MM drugs on the national level (relative increase by 97% from 2012 to 2017), is probably mainly due a massive increase of the prevalent MM population (as 
